Physician profile
Brian Patrick Howard
NPI 1679934871
$3,972.24
in general payments reported to CMS, 2019-2025
18 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $65.03 · 2021: $321 · 2022: $614 · 2023: $990 · 2024: $790 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,873.05 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $306.08 | 2020-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.91 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $254.49 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $242.88 | 2020-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $234.37 | 2021-2024 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $218.16 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $112.51 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $96.03 | 2021-2025 | Trintellix |
| Alkermes, INC. | $92.38 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $77.80 | 2021-2025 | Uzedy |
| Lundbeck LLC | $73.27 | 2022-2025 | Rexulti |
| Tris Pharma INC | $33.13 | 2023 | Dyanavel Xr |
| Allergan, INC. | $20.43 | 2020 | |
| Ironshore Pharmaceuticals INC. | $19.77 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $14.56 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.75 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.